AGREE上肢动力外骨骼恢复手臂功能:单盲随机对照试验
该单盲随机对照试验纳入32例上肢运动障碍的神经科患者,比较AGREE动力外骨骼辅助肩肘运动与常规护理,两组均接受15次、每次45分钟、每周3次的训练。结果显示两组临床量表均显著改善且总体相当,实验组实际治疗时间更少,系统可用性中等,无不良事件。
要点
- AGREE外骨骼辅助训练与常规护理在Fugl-Meyer和ARAT等量表上改善总体相当。
- 实验组实际治疗时间显著少于对照组,但训练次数和总时长相同。
- 系统可用性中等(SUS中位数68.7),治疗师可独立操作,无不良事件。
核心结论
- AGREE上肢动力外骨骼与常规护理在神经科患者上肢功能改善上总体相当,且实验组以更少实际治疗时间获得可比改善。
研究设计与样本
- 单盲随机对照试验,纳入32例上肢运动障碍的神经科患者,随机分为AGREE外骨骼组和常规护理组。
- 两组均接受15次训练,每次45分钟,每周3次。
主要发现
- 实验组Fugl-Meyer评分变化中位数2(IQR=4.5),Action Research Arm Test变化中位数2(IQR=4.5)。
- 两组在所有临床结局指标上均显示可比显著改善,FM和ARAT量表结果略偏向对照组。
- 实验组实际治疗时间显著少于对照组,总训练次数和疗程时长两组相同。
- 系统可用性量表(SUS)中位数68.7(IQR=31.8),治疗师可独立操作AGREE系统,无不良事件发生。
关键数值与推荐
- 可用性采用系统可用性量表(SUS)评估,干预结束时由参与者评定,中位数68.7(IQR=31.8)。
- 临床结局包括Fugl-Meyer Assessment、Action Research Arm Test、Motricity Index和Box and Block Test,从基线至治疗后评估。
临床怎么用
- AGREE外骨骼可由治疗师独立操作,无不良事件,可用于神经科患者上肢运动训练。
- 在相同训练次数和疗程下,外骨骼辅助可能缩短实际治疗时间,提示治疗一致性和频率可能比单次时长更重要。
局限性
- 样本量较小(32例),结论需更大样本验证。
- FM和ARAT量表结果略偏向对照组,需进一步研究最优康复剂量策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Technology-assisted neurorehabilitation is a promising strategy to address the healthcare system overload we are witnessing in recent years. Given the lack of concordance on the effectiveness of upper-limb exoskeletons, it is important to clinically test innovative prototypes. This randomized controlled trial evaluated AGREE, a motorized exoskeleton assisting shoulder and elbow movements with a novel unified control system, against standard care. METHODS: The study involved 32 neurological patients with upper limb motor deficits at Casa di Cura del Policlinico (Italy). The randomization list was generated electronically to allocate participants into two groups. Both groups received 15 training sessions (45 min, three times weekly). The outcome measures considered were: (i) usability (System Usability Scale), (ii) clinical changes in Fugl-Meyer Assessment, Action Research Arm Test, Motricity Index, and Box and Block Test from baseline to post-treatment, and iii) treatment dosage. RESULTS: The usability of the system was evaluated at the end of the intervention by participants with a resulting median SUS score of 68.7 (IQR = 31.8). Both groups showed comparable significant clinical improvements in all clinical outcome measures, with experimental group patients improving both according to the Fugl-Meyer ( Δ FM = 2, IQR =4.5 ) and the Action Research Arm Test ( Δ ARAT = 2, IQR = 4.5). The experimental group received significantly less actual treatment time than the control group, while the total number of sessions and therapy duration were equivalent for the two groups. DISCUSSION AND CONCLUSIONS: Therapists operated the AGREE system independently, and no adverse events occurred. Patients reported a moderate usability of the system. While outcomes slightly favoured the control group for FM and ARAT scales, the obtained results support literature evidence, which indicates that the two treatments are globally comparable. Notably, the experimental group achieved comparable improvements with reduced treatment time, suggesting therapy consistency and frequency may be more impactful than session duration. Future research should further examine optimal rehabilitation dosing strategies.
引用
- Gandolla M, Luciani B, Longatelli V, et al. AGREE: an upper limb motorized exoskeleton for restoring arm functions: a single-blinded randomized controlled trial. J Neuroeng Rehabil. 2025. PMID: 40500718. doi:10.1186/s12984-025-01651-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。